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Abstract
Background: Cognitive impairments, especially deficits of executive function, have been well documented as a
core and early feature in Huntington’s disease (HD). Cognitive impairments represent considerable burden and can
be devastating for people and families affected by HD. Computerised cognitive training interventions that focus on
improving executive function present a possible non-pharmacological treatment option. We propose to determine
the feasibility, acceptability, and appropriate outcome measures for use in a randomised controlled feasibility study.
Methods/design: Participants will be randomised into either a computerised cognitive training group or a control
group. Those randomised to the training group will be asked to complete a cognitive training intervention based
on the HappyNeuron Pro software tasks of executive function, for a minimum of 30 min, three times a week for the
12-week study duration. Participants in the control group will not receive computerised cognitive training but will
receive a similar degree of social interaction via equivalent study and home visits. We will explore quantitative outcome
measures, including measures of cognitive performance, motor function, questionnaires and semi-structured interviews,
as well as magnetic resonance imaging (MRI) measures in a subset of participants. Feasibility will be determined through
assessment of recruitment, retention, adherence and acceptability of the intervention.
Discussion: The results of this study will provide crucial guidance and information regarding the feasibility of conducting
a randomised controlled study into computerised cognitive training in HD. This study is crucial for the development of
larger definitive randomised controlled trials which are powered to determine efficacy and for the development of future
cognitive training programmes for people affected by HD.
Trial registration: The study is registered on clinicaltrials.gov and has the unique identifier NCT02990676.
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Background
Background and rationale
Huntington’s disease (HD) is caused by a CAG repeat
trinucleotide expansion within the first exon of the
huntingtin gene [1], and it causes a range of symptoms
including motor, cognitive and psychiatric disturbances
[2–8]. These disease symptoms significantly affect daily
activities, independence and quality of life, even during the
early stages of the disease [9, 10]. Cognitive dysfunctions
early in the HD disease process have been well documented
and can include specific problems with attention, cognitive
flexibility and memory [11, 12]. Therefore, cognitive training
interventions, which focus on tasks that require executive
function, present a potentially exciting non-pharmacological
treatment option for neurodegenerative diseases including
HD. Studies in HD mice have previously demonstrated
executive function impairments [13, 14], and subsequent
studies have shown that cognitive training can benefit HD
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mice and modify the associated cognitive and motor disease
symptoms [15, 16]. These results provide important ‘proof
of principle’ evidence that an early cognitive training
intervention may be beneficial in HD.
Furthermore, there is accumulating evidence in both
healthy and clinical populations that cognitive training, via
repeatedly conducting tasks that require specific aspects
of executive function such as attention, reasoning, dual
tasking and memory, can improve cognitive functions in
the trained domain [17–20]. For instance, computerised
cognitive training on such tasks has been found to
improve cognitive impairments in Alzheimer’s disease
[21–23] and Parkinson’s disease [24–26]. In addition, a
recent single arm feasibility study demonstrated the feasi-
bility of and adherence to working memory training on the
Cogmed QM programme in a small sample of HD patients
[27]. Furthermore, previous studies have found that
training-related changes are associated with alterations in
white matter, particularly with regard to altered myelination
in both healthy controls [28] and HD [20]. Thus, we intend
to use MRI measures to explore the potential neural
mechanisms which may be associated with computerised
cognitive training in the HD clinical population.
The utilisation of computerised cognitive training
strategies may provide several advantages over repeating
practical tasks [17, 18]. Computerised cognitive training
strategies are automated and often provide adaptive
difficulty levels based on participant performance.
Furthermore, they can be completed by participants at
their convenience, they provide automated tasks which
require comparatively little demand on motor function
and they provide several objective outcome measures
which can be used to detect subtle changes in function
[21–26]. Furthermore, the HappyNeuron cognitive training
software, that we intend to use in this study, can be made
available in different languages to allow for consistent
training globally, and it provides an interface for the
researcher to observe the progress of participants.
Despite this, computerised cognitive training interventions
are yet to be extensively investigated in the HD clinical
population. Therefore, this feasibility study will clarify key
uncertainties regarding the study design, participant eligi-
bility and willingness of potential participants to consent
to the study and be randomised as well as recruitment,
retention and acceptability. It will also facilitate the evalu-
ation of outcome measures and an estimation of effect of
the intervention. This study is a necessary step before
proceeding to a fully powered efficacy trial in the HD
patient population [29].
Aims and objectives
The primary aim of this study is to determine if compu-
terised cognitive training is feasible and acceptable for
people with HD in the setting of a randomised controlled
study. A secondary aim is the exploration of outcome
measures of cognitive function, motor function and ques-
tionnaires. Furthermore, we will explore possible mechan-
istic measures of training-related plasticity through
magnetic resonance imaging (MRI) metrics.
Primary objective
(i) To assess the feasibility of delivering a home-based
computerised cognitive training programme for
people with HD, utilising both quantitative and
qualitative measures considering:
- The willingness of eligible participants to receive
the intervention and participate in a randomised
controlled study
- Potential barriers to recruitment
- Potential barriers to completion of the study
- Response rates and adherence to the computerised
cognitive training programme
Secondary objectives
(i) To explore group effect estimates between the
cognitive training intervention group in comparison
to the control group.
(ii)To use MRI techniques in a subset of participants
to explore the potential neural mechanisms of brain
plasticity that may underpin any observed effects.
(iii)To evaluate the intervention using participant and
family member/carer feedback to inform future
trials in this patient population.
Study design
The proposed study is a randomised feasibility study of
an online computerised cognitive training intervention
for people with HD, to be completed in the home. Those
allocated to the control group will be asked to continue
as normal. All participants will receive home visits. The
home visits will include a battery of cognitive tests for
both groups; those allocated to the intervention will
receive support in setting up the computerised cognitive
training software. Within the overall study, a subgroup
of 16 participants will undergo MRI at baseline, and
approximately 6 weeks into the intervention, MRI will
be offered to participants on a first come first served
basis for those who are eligible and willing. The feasibil-
ity of repeated imaging in this patient population will be
ascertained, and an exploration of the most appropriate
MRI metrics will also be undertaken as part of the feasi-
bility study.
The study schema is illustrated in Fig. 1.
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Methods
Participants, interventions and outcomes
Study setting
Participants will be recruited from the Cardiff HD Centre
at Cardiff University. Study assessments will take place in
the Hadyn Ellis Building (HEB) and Cardiff University
Brain Research Imaging Centre (CUBRIC). Many patients
attending the centre are already participating in the
Enroll-HD observational study (REC no. 04/WSE05/89),
which longitudinally monitors the progression of disease
symptoms. Enroll-HD participants provide permission to
be contacted about other HD research studies and for
their coded data to be accessed by researchers conducting
HD-related research; therefore, these participants will be
approached for this study. As such, a full clinical data set
including full medical and medication history will be
available for each research participant. In addition, we will
seek consent to approach participant family members,
friends and carers for interview, although involvement of a
family member, friend or carer is not a requirement for
participation in the study.
Eligibility criteria
Inclusion and exclusion criteria for the study are shown in
Table 1. The inclusion and exclusion criteria are broad to
determine feasibility for a range of disease stages which
will inform the design and delivery of future trials.
The cognitive training intervention
The 12-week cognitive training intervention, using
HappyNeuron Pro software, will be completed in partici-
pant homes. The software is automated, such that it pro-
vides non-biased data recording and an interface which
allows the researcher to track compliance remotely. It has
previously been validated in both healthy controls [30]
and patients with depression [31] and has shown patient
benefit including improved cognition and functionality.
The cognitive training intervention will comprise six
tasks developed by HappyNeuron which are specifically
aimed at training within the executive function domain.
These tasks include:
1. ‘Writing in the stars’
The participant is given a list of nine words. Only six of
them can be used to fill the empty squares and connect
with each other to form the six-point star. This exercise
aims to train logical reasoning in order to determine which
six words to choose from the list of nine, to find which
positions of letters are common to two or three words.
2. ‘Basketball in New York’
The participant sees a first line of three hoops with
coloured basketballs inside. In the second line, they will
have to determine the number of basketball moves that
are required to reach the same configuration as the first
line of hoops. This exercise aims to train visual mental
imagery as all the possible actions must be visualised in
order to complete the task.
3. ‘Decipher’
The participant is asked to decipher quotations where
the letters have been replaced, either by letters or by
symbols. Each letter is always replaced by the same letter
Fig. 1 Schematic representation of feasibility study
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or symbol. This exercise is designed to train the partici-
pant’s concentration, language (spelling, grammar rules,
letter frequency), logic and the capacity to make deductions
from hypotheses.
4. ‘The Towers of Hanoi’
The participant must configure coloured rings on a series
of pegs to match a target image. There are a number of
rules. The participant can only move one ring at a time and
can never put a larger ring on top of a smaller ring. This
task is designed to train temporal-spatial design, memory
and planning skills. This computerised task is directly
related to the ‘real life’ version which will be completed
during the participant home visits; thus, we will investigate
any possible transfer effects of this training.
5. ‘Hurray for change’
This task comprises two exercises. In the first part, a series
of 4 to 16 letters or words must be linked in alphabetical
order. The second part demands that the participant
alternately sorts two series of items. This exercise requires
concentration and visual and spatial exploration skills. It is
designed to train mental flexibility, visual and verbal working
memory and language skills. This online task is similar in
nature to the trail making tasks which are included as part
of the written study assessments. Thus, we will analyse any
transfer effects.
6. ‘The right count’
In this exercise, the participant is presented with a
series of numbers and mathematical symbols to perform
mental arithmetic calculations. This game trains working
memory, executive function (calculation and arithmetic
reasoning) and mental imagery.
The tasks have an adaptive design in that when
completing the tasks, participants are required to achieve
an 80% level of accuracy twice within the testing period in
order to progress to the next level of the task. If a partici-
pant achieves less than 60% accuracy on a task, they will
be automatically moved to a lower difficulty level. There is
a maximum of nine difficulty levels in each task available
to participants. If a participant reaches level nine, they will
be required to continue at this level for the remainder of
the training. Performance data is recorded at the comple-
tion of each game and is transmitted and stored on the
HappyNeuron server.
Participants will be asked to complete the Happy-
Neuron Pro training for a minimum of 30 min three
times a week for 12 weeks, based on the recommenda-
tions of the software provider. Completion of the cogni-
tive training programme will be supported by email or
telephone reminders and remotely monitored by the
researchers through an interface. The data generated
during the intervention, including the tasks completed,
duration of tasks and levels achieved will be stored
according to HappyNeuron policies and exported to the
researchers upon request.
Participants allocated to the control group will be
asked to continue as normal for the 12-week duration.
The control participants will also receive home visits, to
control for increased social interaction.
Involvement of nominated carers, friends or family
members
The intervention is designed to be completed independently
by the participant. However, as part of this feasibility study,
we will be investigating if any nominated carers, family
members or friends help or aid any of the participants in
completing the intervention. Participants and nominated
carers, friends or family members will be instructed that
they may help the participant if they feel able and willing,
although they are not specifically required to do so. How-
ever, they must not complete the training for the participant.
The involvement of carers, family members or friends may
be an important aspect of the study and something that will
be specifically explored in the semi-structured interviews in
order to inform future trials.
Outcome assessments
As this feasibility study is exploratory in nature, the out-
come measures selected for inclusion in this study will
be utilised to inform future larger trials. Baseline and
outcome assessments will be completed during the study
(Table 2), in addition to MRI measures which will be
completed at baseline and 6 weeks into the intervention.
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Confirmed HD diagnosis by genetic test.
• Over 18 years of age.
• Enrolled in the Enroll-HD study.
• Stable medication regime 4 weeks prior
to recruitment (and not anticipated to change
medications during the study period).
• Inability to provide consent.
• Any known neurological condition (other than HD).
• Currently actively involved in any other interventional trial (i.e. have begun the intervention)
or within 4 weeks of completing the final assessments of an interventional trial.
• Currently regularly completing a computerised cognitive training intervention.
• For the subset of participant’s eligible and willing to have an MRI scan, MRI contraindications
(e.g. a pacemaker) as established using CUBRIC’s standard screening procedures. In addition,
significant levels of disease-related chorea will exclude participants from MRI.
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Table 2 Study outcome assessments
Overall assessment categories are indicated in shaded boxes
*Tests to be included in the extended battery of cognitive assessments to be completed in participant homes during study home visits
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An extended battery of cognitive assessments will be
completed during home visits (Table 2).
Participant timeline
The participant timeline is shown in Table 3.
Withdrawal and loss to follow-up
If a participant wishes to withdraw from the study, they
can inform the researchers conducting the study or any
member of the research team at any time, in person, via
telephone or in writing. If a participant initially consents
but subsequently withdraws from the study, a clear
distinction will be made as to what aspect of the study
the participant is withdrawing from utilising a study
withdrawal form.
Sample size
This is an exploratory feasibility study which aims to
establish the feasibility of conducting a randomised
controlled study into computerised cognitive training
intervention in the HD patient population and provide
evidence for a formal power calculation. We will aim to
recruit 50 participants with a target of randomising 40
participants. The suggested numbers are based on
previous literature regarding cognitive training in other
diseases [21–27]. A subgroup of 16 participants (n = 8 in
the training and n = 8 in the control group) will undergo
MRI scanning before and 6 weeks into the intervention.
Recruitment
An invitation letter and information sheet will be sent to
potential participants who are already participating in the
Enroll-HD study. In addition, Enroll-HD participants may
be approached during their clinical visits and will be
informed of the study. Potential participants will be given
sufficient time to ask questions, discuss the study with the
researchers and discuss the study further with their family
and friends. Potential participants who wish to participate
will be reminded that they can change their mind or
withdraw without reason at any time and that their
decision will not affect the standard care that they receive.
Willing participants will be asked to sign a consent form,
and the initial assessments will then begin.
All potential participants will be screened for their
eligibility based on the inclusion/exclusion criteria. MRI
scanning is an additional component of the study for those
who are eligible. Thus, as part of the screening process,
eligible participants will be screened for contraindications
to MRI and will be asked to sign an additional consent
form which ensures that they understand the potential risks
of MRI.
Assignment of interventions
Sequence generation, allocation concealment mechanism
and implementation
Randomisation will be performed using a minimisation
procedure utilising Minim computer software [32] to ensure
balance between the groups for categorical variables of age
and cognitive function (determined by the categorical verbal
fluency test). Age and cognitive function were chosen as
balancing variables, as they have been shown to be signifi-
cantly associated with cognitive ability [33, 34]; thus, they
will be given the same weighting during the minimisation
procedure. Allocation and the minimization procedure will
be performed by an independent statistician who will input
the balancing variables into the Minim software in order to
provide the group allocation (intervention or control) for
each research participant.
Blinding (masking)
Blinding is not used in this study, due to limited resources
and staffing. Participants allocated to the intervention group
will know that they have been allocated to this group as they
are required to complete the cognitive training intervention.
The lack of blinding is a limitation of the study design; how-
ever, quantitative outcome measures have been utilised
where possible in order to minimise the possible bias that
may be introduced due to a lack of blinding.
Data collection, management and analysis
Data collection methods
Data will be collected on paper case report forms
(CRFs), before subsequent entry into an online database.
Semi-structured interviews will be recorded on a Dicta-
phone before being transcribed verbatim prior to subse-
quent analysis. MRI data will be stored on the secure
CUBRIC database and downloaded on to secure Cardiff
University user accounts to enable further processing
and statistical analysis.
Data management
Electronic data will be stored within firewall- and
password-protected computer systems. No data, whether
paper or electronic, will leave the Cardiff University site
without being completely anonymised. At the conclusion of
the study, patient identifiable data will be destroyed and
non-identifiable data will be archived for 15 years, in line
with Cardiff University policies. Anonymised data may be
shared with researchers at Cardiff University and with other
research organisations in the UK; it may also be made
publicly available for future research use or shared with the
organisations who are funding the study. In the case of the
data generated using HappyNeuron systems, these data are
captured centrally and are therefore subject to HappyNeur-
on’s policies and procedures. All participant identification
and referral procedures as well as procedures for data
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Table 3 Schema of assessments and intervention
Shaded areas indicate subgroups of study assessments
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storage, processing and management will comply with the
Data Protection Act 1998. Data collected on paper forms
will be stored in locked cabinets in a swipe card access-
controlled building, in compliance with the guidelines set
by the Cardiff University Research Governance Framework.
Statistical methods
Adherence to the proposed cognitive training intervention
and any serious adverse events (SAEs) will be reported
alongside participant withdrawals. Summary statistics of
demographics will be reported for both the control and
intervention groups. Descriptive data will include an evalu-
ation of eligibility, recruitment, retention rates and adher-
ence to the intervention, with 95% confidence intervals.
Successful adherence to the intervention will be defined as
having completed 12 weeks of the computerised cognitive
training for a minimum of three, 30-min sessions per week.
This is a feasibility study; thus, an estimation of retention
rates may be difficult with such as small sample size. There-
fore, it is suggested that if retention rates are greater than
75%, we will consider this intervention to be feasible. If the
proportion retained is less than this but greater than 65%,
we will consider adjusting the intervention to increase this
in future investigations.
MRI analysis
Potential cognitive training-related changes in the micro-
structure of white matter pathways of the basal ganglia and
motor systems will be assessed with quantitative metrics
based on diffusion-weighted (fractional anisotropy, mean
and radial diffusivity) and magnetization transfer-weighted
MRI (macromolecular proton fraction as proxy MRI metric
of axon myelin) [35–37]. Changes in basal ganglia volume
will be investigated by extracting subcortical volumes with
the FSL-FIRST pipeline [38]. Changes in cerebral blood flow
will also be investigated across the whole brain as well as
subcortical basal ganglia regions using established methods
[39]. The quantitative metrics of tissue structure and blood
flow will be correlated with changes in cognition to investi-
gate training-related brain-function associations as well as
measures of disease severity, including CAG repeat length,
disease burden and Unified Huntington’s Disease Rating
Scale (UHDRS) motor scores, using data previously
collected and stored as part of the Enroll-HD study.
Semi-structured interview analyses
Interview topics will differ slightly depending on allocation
and are likely to include how the intervention is perceived/
received, expected or perceived impact on daily routine,
expected or perceived impact on family members/carers,
overall expectations, expected or perceived acceptability of
the intervention, thoughts and views on the randomisation
procedure, potential barriers to completing the intervention
and general views or comments on cognitive training for
people impacted by HD.
Interviews will be transcribed verbatim and analysed
using thematic analysis [40]. The data set will be searched
to find repeated patterns of meaning, identifying key
themes and sub-themes. We will identify contradictory
data, as points of contrast as well as similarities in order to
understand uptake and engagement with the intervention.
Double coding will be utilised to ensure data validity,
reliability and integrity. Data will be managed using the
qualitative coding software NVivo.
Monitoring
Data monitoring
As this is a non-Clinical Trial of an Investigational
Medicinal Product (non-CTIMP) feasibility study which
is judged to pose minimal risk to participants, it has
been judged that there is no formal need for a DMC.
However, the Chief Investigator (CI) will produce regular
data monitoring reports to the Centre for Trials
Research (CTR) advisory board. The board will assess
the data quality and monitor this throughout the study.
Harms
The safety of the proposed cognitive training intervention
will be monitored throughout the feasibility study by
recording of all adverse events (AE). Based on the use of
this cognitive intervention programme in a similar patient
population with other neurodegenerative diseases [24], we
do not anticipate any serious adverse events (SAEs)
related to the intervention. However, safety will be moni-
tored throughout and any AEs or SAEs will be recorded
using a standard template and reported in line with
standard operating procedures and research ethics
committee requirements. If, in the opinion of the CI, the
SAE was related to the administration of any of the
research procedures and was an unexpected occurrence,
the CI will report this to the REC within 15 days of
becoming aware of the event. If the clinician responsible
for the clinical care of participants deems that it is clinic-
ally necessary to stop the intervention, the participant will
be withdrawn from the intervention. However, the partici-
pant will still be invited to complete the outcome assess-
ments. Relapse, worsening of symptoms of HD, death due
to HD and hospitalisations for elective treatment of a pre-
existing condition will not be reported as SAEs.
MRI and incidental findings
MRI scanning at 3 Tesla is a well-established and non-
invasive technique for imaging the body and the brain
using strong magnetic fields and low-energy radio waves.
It does not involve the use of radiation. All persons
entering the scanning room are screened for ferromagnetic
materials or other factors which cause risk in the presence
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of a strong magnetic field. The scanner creates significant
noise during the scan, which is minimised using earplugs.
Verbal contact will be maintained between the MRI
operators and the participant through the use of
intercom, and a call button will be given to the participant
to enable them to stop the scanning procedure at any
time. A few people have reported minor side effects during
MRI scanning including dizziness, mild nausea, a metallic
taste in the mouth, peripheral nerve stimulation and the
sensation of seeing flashing lights. These side effects, if
experienced, resolve after leaving the magnet, and partici-
pants will be informed in the participant information sheet
(PIS) of the MRI scanning session of these rare side effects.
Some people find being inside an MR scanner claustropho-
bic; thus, in addition to the 3 Tesla MR machine, CUBRIC
also has a ‘mock’ scanner that reproduces, as far as possible,
the look and feel of the real MR machine, but without the
presence of a magnetic field. Participants will be given the
opportunity to lie in this ‘mock’ scanner to acclimatise in
advance of the real MRI scan session. If the participant finds
the experience in either scanner unpleasant, then he/she
would be removed from the scanner.
In some circumstances, changes in the magnetic field
within the MRI scanner could make an electric current flow
through some of the volunteer’s body, causing peripheral
nerve stimulation; this is very rare for the 3 Tesla MRI scan-
ner and not harmful but may be uncomfortable. If two parts
of the volunteer’s body were touching (for instance legs
crossed), then in very rare occasions, it is possible that an
induced current may cause skin heating. Volunteers are
instructed to lie with their arms to their sides and legs
uncrossed, which stops this from happening. Participants
will be informed that CUBRIC is a research centre and
therefore cannot provide clinical diagnoses; acquired images
of the brain are used for specific research purposes only and
not suitable for diagnosis of pathology. However, although
the pictures are not diagnostic scans, in the unlikely event of
a structural abnormality being noted incidentally, a neuro-
radiologist would be asked to review the scan and the
clinical lead of the study will be informed. The participant’s
general practitioner (GP) will then be notified by the
neurologist. There may be a need for the GP to arrange for
a formal diagnostic scan.
Auditing
The study is subject to inspection by The Jacque and
Gloria Gossweiler Foundation and Health and Care
Research Wales as the funding organisations. The study
may also be subject to inspection and audit by Cardiff
University under their remit as sponsor.
Consent
Potential participants will be given as long as they need to
read the PIS, consider the study and discuss it with the
researchers or friends or family, as required. Informed
consent will then be obtained by means of a participant
dated signature and a dated signature of the person who
obtained the informed consent. Participants will be asked
during the consent process if their family member, friend
or carer can be asked their opinions of cognitive training
interventions. If participant consent is provided to ask
family members, friends or carers for their opinions, they
will be asked to read a separate participant information
sheet (PIS) and provide their consent by means of a dated
signature and a dated signature of the person who
obtained the informed consent. The friend or family
member will then be asked to complete a semi-structured
interview similar to that described above.
Confidentiality
All participant identification and referral procedures as
well as procedures for data storage, processing and
management will comply with the Data Protection Act
1998. Data will be kept for 15 years in line with Cardiff
University’s Research Governance Framework Regulations
for clinical research. This data will be stored confidentially
on password protected servers maintained on the Cardiff
University Network. Data collected on paper forms will be
stored in locked cabinets, and electronic data will be
stored on secured computer hard drives (password pro-
tected) in a swipe card access-controlled building, in com-
pliance with the guidelines set by the Cardiff University
Research Governance Framework. The confidentiality of
participants will be preserved in accordance with the Data
Protection Act 1998. All participants will be allocated a
unique study number identifier, and in the case of family
members, friends or carers, they will be allocated a unique
study number in relation to the participant. All data
collected will be held in a linked anonymised form.
Dissemination policy
The research team are committed to disseminating the
research findings to the general public and to patient
groups; therefore, we will seek to present the results at
patient open days, engagement events and outreach activ-
ities. Furthermore, in order to communicate the research
widely, the results may be disseminated via social media,
through newsletters and other patient engagement outlets
in appropriate language and format for the general public
to understand. If a participant indicates that they would like
to be informed of the results of the study, a report of the
findings will be sent to them at study closure. Where
results are presented, they will always be presented in such
a way that data from individual participants cannot be iden-
tified. In addition to the significant public and patient out-
reach dissemination, the research findings will be written
up for publication in a scientific journal. The results may
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also be presented at scientific meetings, academic institu-
tions or as part of public engagement and outreach events.
Protocol version and amendments
This publication is based on protocol version 4.0
_31.07.2017. The protocol has been written in line
with both the CONSORT (Consolidated Standards of
Reporting Trials) statement [41] and SPIRIT (Standard
Protocol Items: Recommendations for Interventional
Trials) guidelines [42]. Any updated protocols will be
communicated to the study team via email and telephone
as appropriate.
Sponsor information
Sponsorship is provided by Cardiff University (SPON
1535-16).
The study receives advisory support from The Centre
for Trials Research, Cardiff University.
Discussion
The cognitive training intervention described in this
protocol was developed based on the recommendations of
the software providers (HappyNeuron) as well as consid-
ering the views of people affected by HD, their family
members and friends. During this study, as well as captur-
ing participant views in qualitative semi-structured inter-
views, we will also aim to consider the views of family
members, friends and carers in our analysis of feasibility.
Family member, friend and carer involvement in the study
will be crucial in determining if this intervention is feas-
ible and able to be completed independently. This will be
vital in future studies which may seek to use computerised
cognitive training that is completed in participant homes.
In this feasibility study, the proposed computerised
cognitive training intervention is supported by home visits
and email or telephone reminders. As a result of this, any
changes in outcome measures may be attributed to social
interaction. Therefore, the control participants will also
receive home visits, to control for increased social inter-
action. Furthermore, it is possible that any observed
changes may be attributed to the increased use of a com-
puter. Whilst we have not included them in this in this
study, should feasibility be established in future trials, it
may be prudent to include additional control groups to
explore the generalised effect of computer use in this pa-
tient population. Additional control groups could also be
considered to explore the effect of home visits, reminders
and support provided to participants.
The primary aim of this study is to determine the
feasibility of conducting a randomised controlled,
computerised cognitive training study for people with
HD. Therefore, we will explore the willingness of eligible
participants to be randomised, to receive and participate
in the intervention, any potential barriers to recruitment
or completion and response rates and adherence to the
cognitive training programme. This feasibility study has
not been powered for hypotheses testing, but the data
gathered will inform the design and delivery of future
larger trials, including providing vital information to
inform sample size estimates. Crucial inferences will
be made which will allow an estimation of parameters
that can inform definitive and future trials in this
specific patient population.
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